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Summary. Tumour necrosis factor-alpha (TNF) is a major 
mediator ofdiverse pathophysiological events similar to those 
of haemolytic transfusion reactions (HTR), such as fever, 
intravascular coagulation and organ failure. However, the 
possible role of TNF in HTR has not been investigated. We 
have constructed an in vitro whole blood model of HTR to 
examine whether TNF may be produced in red cell ABO 
incompatibility. TNF was observed in plasma, in a dose 
dependent manner, when ABO incompatible red cells were 
added, but not with compatible (group 0) cells. Plasma TNF 
levels were maximal at 2 h, and declined to control levels by 
24 h. Haemolysis of incompatible red cells was accompanied 
by TNF production. Immune haemolysis induced TNF gene 
expression by buffy coat leucocytes, as determined by 
Northern blot analysis. Heat inactivation of plasma abolished 
TNF production, whereas prior treatment with interferon- 
gamma augmented the response. These results demonstrate 
that a major cytokine is produced in response to red cell 
incompatibility, and suggest that TNF may play a role in the 
pathogenesis of haemolytic transfusion reactions. 
Knowledge of the pathophysiological events involved in 
haemolytic transfusion reactions (HTR) has lagged behind 
progress in our understanding of the inflammatory response, 
especially with respect to the role of cytokines. The cytokine 
tumour necrosis factor-alpha (TNF) has been shown to play a 
significant role in mediation of septic shock (Tracey L!? Cerami, 
1989). Biological activities attributed to TNF include: fever, 
shock, capillary leakage, leucocyte chemotaxis, activation of 
leucocytes and endothelial cells, and activation of the 
intrinsic coagulation cascade (Morimoto et al, 1989; Ste- 
phensetal. 1988: Meyeretal. 1988: Selbyetal, 1987: Spriggs 
etal, 1987: Schleefetal, 1988:Berkowetal, 1987:Hoffman& 
Weinberg. 1987: van der Poll et al, 1990). Septic shock 
shares many clinical characteristics with the syndrome of 
acute haemolytic transfusion reaction, including fever, 
shock, organ failure, intravascular coagulation, and death 
(Pineda et al, 1978). Previous investigations have shown that 
TNF is produced in whole blood, in vitro. in response to 
lipopolysaccharide challenge (Strieter et al, 1990). We 
therefore considered that TNF may be produced in whole 
blood during HTR, and, accordingly, developed a unique 
experimental model to investigate this question. 
Correspondence: Dr R. D. Davenport, Department of Pathology, 
University of Michigan Hospitals 20332/0054. Ann Arbor, Michi- 
gan 48109-0054. U.S.A. 
MATERIALS AND METHODS 
Blood. Whole blood (WB) was obtained from group 0 
normal volunteers drawn into heparin (50 USP U/ml). Red 
blood cells (RBC) were obtained from normal volunteer 
donors, drawn into CPDA-1 anticoagulant. The ABO types of 
WB and RBC were confirmed by standard haemagglutination 
techniques. Donors of WB lacked unexpected alloantibodies. 
RBC were washed three times with normal saline, and the 
buffy coat removed. WB was aliquoted into 5 ml polypropy- 
lene tubes containing 2 ml each. Washed packed RBC 
(haematocrit. 82 fO.02) were added in amounts indicated 
under Results. The tubes of blood were placed on a rocker in 
an incubator at 37OC with 5% C02  for times indicated below. 
In some experiments plasma was separated from WB, heated 
to 56OC for 1 h to inactivate complement, and recombined 
with the cellular elements that had been washed three times 
in normal saline. In some experiments 100 U/ml interferon- 
gamma was added to WB and incubated for 4 h before RBC 
were added. When tubes were removed for the incubator, 
they were centrifuged for 5 min at 600 g. The plasma was 
removed for TNF bioassay. The buffy coat was removed and 
placed into RBC lysing buffer for 2 min. Leucocytes were 
recovered by centrifugation at 600 g for 3 min. and RNA was 
extracted as below. 
TNF bioassay. Plasma concentrations of TNF were mea- 
sured using the WEHI 164 subclone 13 cell line, as previously 
described (Espevik 81 Nissen Meyer. 1986). Briefly, samples 
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Fig 1. Mean ( f SEM) of plasma TNI: (part A )  and haemoglobin concentrations (part B) at 2 h as a function of dose of RBC. Significant differences 
between incompatible group A RBC and compatible group 0 RBC ( P < O . O 5 )  are indicated by *. Each point represents mean of three observations. 
Packed red cells were added to whole blood in amounts indicated. Plasma was separated from cells at 4 h. 
were serially diluted in flat-bottom 96-well microtitre plates 
(Costar. Cambridge. Mass.) using a multipipettor. Cells were 
resuspended in KPMI 1640 (Whitaker Biomedical Products, 
Whitaker. Calif.) with 10% fetal calf serum, 1 mM L- 
glutamine. and 0 . 5  pg/ml actinomycin D to a concentration 
of 5 x I 04/ml and added to the diluted samples (0.1 ml/well). 
Plates were allowed to incubate for 18-20 h at  37°C and 5% 
C 0 2 .  2 0  pI of MTT-tetrazolium ( 5  mg/ml, Sigma Chemical 
Co.) was added to each well and allowed to incubate an 
additional 4 h. 1 5 0  pI of supernatant fluid was removed and 
100 p1 of 0.04 N HCl/isopropanol added to each well. The 
plates were stored overnight in the dark and then read on a 
microtitre plate reader (Bio-Tek Instruments. Inc., Winooski, 
Vt.) using a 5 50 nm filter. TNF units were calculated based on 
a standard curve generated with human recombinant TNF 
with a specific activity of 22 units/ng protein (Cetus Corp., 
Emeryville. Calif.). 
Northern blot analysis. Total RNA was isolated from buffy 
coat leucocytes as previously described (Kunkel e l  al. 1988). 
Briefly, 3 ml of 25 nM Tris, pH 8.0,  containing 4.2 M 
guanidine isothiocyanate. 0.5% sarkosyl and 0.2 M 2- 
mercaptoethanol were added to each tube and homogenized. 
An equal volume of 100 mM Tris. pH 8.0.  containing 10 mM 
EDTA and 1 SDS was added and the mixture extracted 
with chloroform-phenol and chloroform-isoamyl alcohol. 
The KNA was alcohol precipitated, and the pellet dissolved in 
1 0  mM Tris/O. 1 mM EDTA buffer with 0.1 % sarkosyl. The 
KNA was electrophoresed using formaldehyde/l % agarose 
gels. The separated KNA was transblotted to nitrocellulose, 
baked, prehybridized, and hybridized with a 30-mer "P-5' 
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Fig 2. Time dependence of mean (+SEM) plasma TNF following addition of 6 pI RBC/ml WB. Significant differences between incompatible group A 
RBC and compatible group 0 RBC (P<0.05) are indicated by *. Each point represents mean of three observations. 
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Fig 3. Northern blot of buffy coat mRNA isolated 1 h following 
addition of incompatible RBC (lane 1) .  or compatible RBC (lane 2) 
probed for TNF. Total RNA (part A) shows equal loading of lanes. 
Autoradiograph (part B) demonstrates 1.6 kb TNF mRNA with red 
cell incompatibility. Blood was pretreated with cycloheximide to 
inhibit protein synthesis (see Results). 
end-labelled synthetic oligonucleotide probe for TNF, 5’- 
ACA-AGC-ACC-GCC-TGG-AGC-CCT-GGG-GCC-CCC-3’. anti- 
sense to nucleotides 150- 179 of the TNF cDNA (Wang et a/ .  
1985). Blots were washed and autoradiographed with 
intensifying screens. 40 p g  RNA was loaded per lane. 
Plasma haemoglobin. Plasma haemoglobin concentrations 
were determined by the benzidine oxidation method as 
described (Crosby & Furth. 19 56). 
Statistics. Paired data were compared by the Student t-test. 
as indicated in the figure legends. 
RESULTS 
TNF was produced in a dose and time dependent manner 
when incompatible RBC were added to group 0 whole blood. 
However, when compatible (group 0) RBC were added, no 
TNF production occurred. Addition of group A, B or AB RBC 
caused TNF production that was indistinguishable between 
each of these three conditions. Incubation of RBC in plasma 
devoid of leucocytes resulted in haemolysis of incompatible 
RBC, as expected, without TNF production. 
The concentration of TNF in plasma was dependent on the 
amount of incompatible red cells added (Fig 1 ) .  The highest 
level was observed with 6 p1 of packed RBC per ml of WB. 
Statistically significant differences from group 0 RBC 
(P<0.05) wereobserved in the range of 3-12 pl/ml WB. The 
degree of haemolysis. as determined by plasma haemoglobin 
concentrations, paralleled the curve of plasma TNF produc- 
tion (Fig 1) .  The decrease in both haemolysis and TNF 
production with larger amounts of incompatible RBC most 
likely reflects the consumption of a critical intermediate, 
possibly a complement component, in this closed system. 
Plasma TNF levels significantly above control were 
observed at 2 h after addition of incompatible RBC (Fig 2). At 
24 h TNF levels were no different than with group 0 RBC. 
Haemolysis of incompatible RBC was complete at 2 h. No 
haemolysis occurred with group 0 RBC. The optimal condi- 
tion for TNF production was 6 pI incompatible RBC per 1 ml 
WB incubated 2 h. Addition of lipopolysaccharide 10 pg/ml 
did not cause haemolysis. but did result in TNF production 
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Fig 4. Effect of pretreatment conditions. Bars represent mean (+SEM) of three observations ( 1 2  pI RBC/ml WB. incubated 4 h). ( A )  Blood 
reconstituted with heat inactivated plasma (heated) did not respond to incompatible red cells. Significant differences ( P  ~ 0 . 0 5 )  between blood 
reconstituted with normal plasma (unheated) stimulated with incompatible group A RBC and heated with A RBC or unheated with compatible 0 
RBC. ( B )  Blood pretreated with y-interferon (11 IFN) 4 h before addition of RBC showed enhanced response to incompatible RBC ( P c O . 0 5 ) .  
Difference in plasma TNF between y IFN treated and untreated blood with compatible RBC was not statistically significant. 
(1027+ 128 U/ml at 4 h). Addition of recombinant human 
TNF 100 U/ml did not cause haemolysis. 
To determine if immune haemolysis induced TNF gene 
transcription, buffy coat RNA was extracted and subjected to 
Northern blot analysis. TNF mRNA was barely detectable a t  
the time of peak response, 2 h following RBC addition. 
However, TNF gene expression in response to incompatible 
RBC could be superinduced with 5 pg/ml cycloheximide 
added 1 h after RBC (Fig 3 ) .  indicating that as with 
lipopolysaccharide stimulation of mononuclear cells, TNF 
gene expression is most likely under the control of short-lived 
repressor proteins (Colart et al. 1986). 
When plasma was separated from WB. heated to 56°C for 1 
h to inactivate complement and recombined with the washed 
cellular elements, both haemolysis and TNF production were 
abolished (Fig 4A). Agglutinating isoantibodies. however, 
were still present. This observation, in conjunction with the 
parallel dose relationship of haemolysis and TNF production, 
suggests that complement is a necessary intermediate in 
leucocyte activation due to ABO red cell incompatibility. 
To determine if activation of WB with interferon-gamma 
altered TNF production, as with lipopolysaccharide stimula- 
tion (Collart et al. 1986: Beutler et al. 1986), WB was 
pretreated with 100 U/ml interferon-gamma 4 h before 
addition of KBC. which resulted in a significant augmen- 
tation of TNF production in response to incompatible RBC 
(Fig 4B. P < 0 4 5 ) .  There was no statistically significant 
difference in TNF levels with interferon-gamma pretreatment 
and compatible RBC. 
DISCUSSION 
Present concepts of the pathogenesis of haemolytic trans- 
fusion reactions have focused primarily on the role of 
immune complexes in the activation of Hageman factor to 
trigger the coagulation and kinin systems, and the activation 
of the complement system to produce the anaphylotoxins 
C3a and C5a. as well as red cell lysis (Goldfinger, 1977). 
However, few experimental data are available to support 
these hypotheses. Our results provide evidence that, in 
addition to these mediators, TNF may play a significant role 
in the pathological response to incompatible red cell trans- 
fusions. Several of the cardinal signs and symptoms of HTR 
may be mediated by TNF. Fever accompanied by rigours 
occurs upon infusion of recombinant human TNF at  doses 
producing plasma levels similar to those observed in this 
model (Selby et al, 1987: Spriggs et al. 1987). Also. intravas- 
cular coagulation may be induced by TNF through activation 
of the intrinsic pathway, or by induction of tissue factor and 
plasminogen activator inhibitor in endothelial cells (Schleef 
et al. 1988: van der Poll et al. 1990). This latter effect of TNF 
may be of particular significance in HTR as evidenced by the 
histological similarities between the lesions caused by lipo- 
polysaccharide and HTR. 
Infusion of lipopolysaccharide. a potent stimulus for TNF. 
or of recombinant human TNF. results in acute renal tubular 
necrosis, intestinal infarction, and pulmonary haemorrhage 
with thrombosis and neutrophil accumulation, which is 
prevented by pretreatment with monoclonal antibody 
against TNF (Tracey et al, 1986). Experimental injection of 
incompatible blood produces similar histological lesions 
(Hardaway et al, 1956: McKay et al, 1956). Thrombi are 
found in pulmonary vessels with numerous leucocytes. 
Haemorrhagic necrosis occurs in the colon and small 
intestine. Acute tubular necrosis, haemoglobin casts, and 
thrombi are seen in the kidneys. Thrombosis dominates in 
animals that died shortly after red cell injection, whereas 
renal tubular necrosis and mucosal necrosis in the gastroin- 
testinal tract are seen at  later times. 
Immune haemolysis has not been previously described as a 
stimulus for the production of TNF. The abolition of the 
response by heat treatment of plasma and the parallel 
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relationship of haemolysis and TNF production strongly 
suggests that complement activation, and binding of comple- 
ment products to monocyte surface receptors, is a necessary 
intermediate. Furthermore, augmentation of the response by 
pretreatment with interferon-gamma, which has also been 
observed with lipopolysaccharide stimulation of monocytes, 
as well as superinduction of TNF mRNA expression by 
cycloheximide suggest that common postreceptor pathways 
of TNF production are involved (Collart et al. 1986: Beutler et  
al. 1986). Although the role of cytokines in the pathophysio- 
logy of transfusion reactions remains to be completely 
elucidated, there is accumulating evidence that they play a 
role in producing the effects of incompatible red cell trans- 
fusion. Interleukin-8, another cytokine with chemotactic and 
activating effects on neutrophils, has also been shown to be 
produced in red cell incompatibility (Davenport et al, 1990). 
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